280 related articles for article (PubMed ID: 28143867)
21. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
[TBL] [Abstract][Full Text] [Related]
22. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
25. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
[TBL] [Abstract][Full Text] [Related]
27. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
28. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Natoli C; Vici P; Sperduti I; Grassadonia A; Bisagni G; Tinari N; Michelotti A; Zampa G; Gori S; Moscetti L; De Tursi M; Panebianco M; Mauri M; Ferrarini I; Pizzuti L; Ficorella C; Samaritani R; Mentuccia L; Iacobelli S; Gamucci T
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1229-40. PubMed ID: 23604446
[TBL] [Abstract][Full Text] [Related]
30. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract][Full Text] [Related]
31. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
Takada M; Ishiguro H; Nagai S; Ohtani S; Kawabata H; Yanagita Y; Hozumi Y; Shimizu C; Takao S; Sato N; Kosaka Y; Sagara Y; Iwata H; Ohno S; Kuroi K; Masuda N; Yamashiro H; Sugimoto M; Kondo M; Naito Y; Sasano H; Inamoto T; Morita S; Toi M
Breast Cancer Res Treat; 2014 May; 145(1):143-53. PubMed ID: 24682674
[TBL] [Abstract][Full Text] [Related]
32. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Ann Oncol; 2019 Jun; 30(6):927-933. PubMed ID: 30903140
[TBL] [Abstract][Full Text] [Related]
33. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
34. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Swain SM; Tang G; Lucas PC; Robidoux A; Goerlitz D; Harris BT; Bandos H; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2019 Nov; 178(2):389-399. PubMed ID: 31428908
[TBL] [Abstract][Full Text] [Related]
35. The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas.
Ji H; Xuan Q; Nanding A; Zhang H; Zhang Q
PLoS One; 2015; 10(7):e0132824. PubMed ID: 26161550
[TBL] [Abstract][Full Text] [Related]
36. Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic.
Zuazana B; Luboš P; Renata C
Klin Onkol; 2018; 31(3):191-199. PubMed ID: 30441972
[TBL] [Abstract][Full Text] [Related]
37. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
[TBL] [Abstract][Full Text] [Related]
39. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
40. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
